Revolution Medicines reports Phase 3 pancreatic cancer trial success, raises $2.2B

Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read

Key Changes

• high

  Daraxonrasib showed median overall survival of 13.2 months vs. 6.7 months for chemotherapy in Phase 3 pancreatic cancer trial (hazard ratio 0.40, p<0.0001); company plans regulatory submissions including FDA filing.

  Exhibit 99.1 verify on EDGAR →
• high

  Raised $2.225 billion gross proceeds through concurrent offerings: $1.725 billion in common stock and $500 million in 0.50% convertible notes due 2033, receiving $2.1 billion net in April 2026.

  Exhibit 99.1 verify on EDGAR →
• high

  Q1 2026 net loss of $453.8 million, more than double the $213.4 million loss in Q1 2025, driven by higher R&D expenses ($344.0M vs. $205.7M) and G&A expenses ($101.3M vs. $35.0M).

  Exhibit 99.1 verify on EDGAR →